Citations

Clear

3042 citation(s) found for "Kumar, S".

Cushing’s Syndrome After Intra-articular and Intradermal Administration of Triamcinolone Acetonide in Three Pediatric Patients
Kumar, Seema , Reed, Ann M., Lteif, Aida, Singh, Ravinder

Mayo Clinic

Pediatrics | August 14, 2004 | Volume: 113 | Issue: 6 | Pages: 1820-1824

10.1542/peds.113.6.1820 | PMID 15173517 Get It

Background. Intra-articular and intradermal steroids are often used for their antiinflammatory effect. There is limited experience with intra-articular and intralesional administration of corticosteroids in the pediatric age group. Design/Methods. We performed a retrospective chart review of 3 pediatric patients who developed Cushing’s syndrome after local administration of triamcinolone acetonide (TCA). Results. Two females 9 and 17 years old, received intra-articular injections of TCA. One patient received multiple injections of TCA into the interphalangeal joints (cumulative dose: 120 mg), whereas the other received a single injection of 40 mg, a dose that is considered to be in the therapeutic range, into the hip joint. The third patient, a 7-year-old female, received multiple intralesional injections of TCA. These patients developed signs and symptoms of hypercortisolism that appeared 4 to 6 weeks after local administration of TCA and lasted for 4 to 6 months after the last dose of TCA. TCA was detectable in the plasma and urine by the liquid chromatography/tandem mass spectrometry method 4 to 5 months after the last dose of the steroid. Conclusions. We noted evidence for Cushing’s syndrome in 3 pediatric patients after intra-articular or intradermal administration of TCA. One of them had received a therapeutic dose of TCA. The possibility of hypothalamic-pituitary-adrenal axis suppression should be considered in patients who have received intra-articular or intradermal steroid injections, particularly in those who have had multiple or relatively high doses.
Thalidomide: Current Role in the Treatment of Non-Plasma Cell Malignancies
Kumar, Shaji , Rajkumar, S. Vincent , Witzig, Thomas E. , Rajkumar, S Vincent

Mayo Clinic

Journal of Clinical Oncology | June 15, 2004 | Volume: 22 | Issue: 12 | Pages: 2477-2488

10.1200/jco.2004.10.127 | PMID 15197211 Get It

Thalidomide, initially introduced as a sedative, was withdrawn from the market in the early 1960s after it was found to be a teratogen. However, it later found use as an investigational agent in the treatment of erythema nodosum leprosum, oral ulcers, graft versus host disease, and wasting associated with the human immunodeficiency syndrome. Its antiangiogenic properties were recognized in the early 1990s during a period where the importance of angiogenesis became increasingly apparent as a critical step in the in the proliferation and spread of malignant neoplasms. This led to the evaluation of thalidomide as an antiangiogenic agent in the treatment of several cancers. Thalidomide has already become part of standard therapy for the treatment of patients with relapsed and refractory multiple myeloma. It has also been found to have varying degree of benefit in various other malignancies. Although more clinical trials are needed, Kaposi's sarcoma and myelofibrosis represent other malignancies in which thalidomide has already demonstrated promising activity. The mechanism of action of thalidomide in cancer is still unclear, but do appear to be mediated by several other mechanisms in addition to its anti-angiogenic properties. This article reviews the current status of thalidomide for the treatment of non-plasma-cell malignancies.
Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression
Kumar, Shaji , Timm, Michael, Haug, Jessica, Wellik, Linda, Kimlinger, Teresa K. , Greipp, Philip R., Rajkumar, S. Vincent , Witzig, Thomas E. , Rajkumar, S Vincent

Mayo Clinic

Blood | May 11, 2004 | Volume: 104 | Issue: 4 | Pages: 1159-1165

10.1182/blood-2003-11-3811 | PMID 15130943 Get It

AbstractWe compared the angiogenic potential of bone marrow plasma and the expression of vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and their receptors on plasma cells from patients with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and newly diagnosed multiple myeloma (NMM). Cytokine and cytokine-receptor expression was studied by bone marrow immunohistochemistry, quantitative reverse transcription-polymerase chain reaction (RT-PCR) on sorted plasma cells, and quantitative Western blot analysis. Bone marrow angiogenic potential was studied using a human in vitro angiogenesis assay. The expression levels of VEGF, bFGF, and their receptors were similar among MGUS, SMM, and NMM. Sixty-one percent of NMM samples stimulated angiogenesis in the in vitro angiogenesis assay compared with SMM (0%) and MGUS (7%) (P < .001). Importantly, 63% of MGUS samples inhibited angiogenesis compared with SMM (43%) and NMM (4%) (P < .001). The inhibitory activity was heat stable, not overcome by the addition of VEGF, and corresponded to a molecular weight below 10 kd by size-exclusion chromatography. Our results suggest that increasing angiogenesis from MGUS to NMM is, at least in part, explained by increasing tumor burden rather than increased expression of VEGF/bFGF by individual plasma cells. The active inhibition of angiogenesis in MGUS is lost with progression, and the angiogenic switch from MGUS to NMM may involve a loss of inhibitory activity. (Blood. 2004; 104:1159-1165)
The ‘red Ear Syndrome’ Revisited: Two Cases and a Review of Literature
Kumar, Neeraj , Swanson, JW

Mayo Clinic

Cephalalgia | March 19, 2004 | Volume: 24 | Issue: 4 | Pages: 305-308

10.1111/j.1468-2982.2004.00666.x | PMID 15030541 Get It

The first description of what subsequently came to be known as the red ear syndrome (RES) was by Lance in 1994 (1) (Table 1, cases 2-4). Subsequently he reported a total of 12 patients with what he called the red ear syndrome (2) (Table 1). The syndrome was characterized by attacks of unilateral ear discomfort or burning during which the ear became red. The discomfort often extended beyond the ear. He reported an association with upper cervical disorders, glossopharyngeal and trigeminal neuralgia, temporomandibular joint (TMJ) dysfunction, and a thalamic syndrome. In two of the 12 cases (Table 1, cases 11 and 12) no cause was apparent. In some cases the episodes were spontaneous and in others they were precipitated by touch, exertion, heat or cold, neck movements, stress, cleaning the ear, washing hair or brushing it the wrong way, and eating or drinking. While some of their patients had a history of headaches (including migraines), a consistent relationship to migraine headaches was not identified.
Relative Overexpression of Macrophage-Derived Cytokines in Orbital Adipose Tissue from Patients with Graves’ Ophthalmopathy
Kumar, Seema , Bahn, Rebecca S.

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | September 12, 2003 | Volume: 88 | Issue: 9 | Pages: 4246-4250

10.1210/jc.2003-030380 | PMID 12970294 Get It

Graves’ ophthalmopathy (GO) is an autoimmune disorder involving the adipose and connective tissues of the orbit. The study of cytokines present in these tissues may reveal the nature of the cells and immune responses involved in GO pathogenesis. In the current study, we performed relative quantification of the expression of cytokine genes in orbital adipose tissue from patients with GO (n = 6) and normal individuals (n = 2). Real-time RT-PCR was performed using fluorescent probes and primers for cytokines including IL-1β, IL-2, IL-4, IL-5, IL-8, IL-10, IFN-γ, and TNF-α. Results showed IL-1β to be the gene having the greatest fold expression increase over normal in four of six patients. TNF-α was increased in all six GO patients. In addition, IL-8, IL-10, and IFN-γ were increased in five of six GO patients. We found no evidence of either IL-4 or IL-5 expression in any of the GO or normal samples. The increased expression of the macrophage-derived cytokines IL-1β, TNF-α, and IL-10 suggests the presence of macrophage activation and ongoing antigen presentation within the orbit in GO. In addition, the overexpression of IFN-γ, without evidence of IL-4 or IL-5 expression, supports the concept that cell-mediated, rather than humoral, immunity plays the predominant role in pathogenesis of this disorder.
Amyloid-β peptide levels in brain are inversely correlated with insulysin activity levels in vivo
Miller, Bonnie C., Eckman, Elizabeth A. , Sambamurti, Kumar , Chow, K. Martin, Eckman, Christopher B., Hersh, Louis B., Thiele, Dwain L., Dobbs, Nicole

Mayo Clinic

Proceedings of the National Academy of Sciences | May 13, 2003 | Volume: 100 | Issue: 10 | Pages: 6221-6226

10.1073/pnas.1031520100 | PMID 12732730 Get It

Factors that elevate amyloid-β (Aβ) peptide levels are associated with an increased risk for Alzheimer's disease. Insulysin has been identified as one of several proteases potentially involved in Aβ degradation based on its hydrolysis of Aβ peptides in vitro . In this study, in vivo levels of brain Aβ40 and Aβ42 peptides were found to be increased significantly (1.6- and 1.4-fold, respectively) in an insulysin-deficient gene-trap mouse model. A 6-fold increase in the level of the γ-secretase-generated C-terminal fragment of the Aβ precursor protein in the insulysin-deficient mouse also was found. In mice heterozygous for the insulysin gene trap, in which insulysin activity levels were decreased ≈50%, brain Aβ peptides were increased to levels intermediate between those in wild-type mice and homozygous insulysin gene-trap mice that had no detectable insulysin activity. These findings indicate that there is an inverse correlation between in vivo insulysin activity levels and brain Aβ peptide levels and suggest that modulation of insulysin activity may alter the risk for Alzheimer's disease.
Expression of CD52 on plasma cells in plasma cell proliferative disorders
Kumar, Shaji , Kimlinger, Teresa K. , Lust, John A., Donovan, Kathleen A., Witzig, Thomas E.

Mayo Clinic

Blood | April 29, 2003 | Volume: 102 | Issue: 3 | Pages: 1075-1077

10.1182/blood-2002-12-3784 | PMID 12714489 Get It

Abstract Multiple myeloma (MM) and primary systemic amyloidosis (AL) remain incurable disorders, and new treatments targeted to the malignant plasma cells are needed. Alemtuzumab is a humanized monoclonal antibody to CD52 and has activity in chronic lymphocytic leukemia. We examined the CD52 expression on CD45+ and CD45- plasma cell populations to evaluate the potential for using alemtuzumab for these disorders. Bone marrows from 61 patients (29 AL, 23 MM, and 9 MGUS [monoclonal gammopathies of undetermined significance]) were studied using 3-color (CD38/45/52) flow cytometry. Among those with MGUS, MM, and AL, 67%, 52%, and 35%, respectively, were positive for CD52 expression. The CD52 expression was predominantly confined to the clonal CD38+/CD45+ plasma cell fraction with median expression of 68%, 88%, and 82% in MGUS, MM, and AL, respectively, compared with 18%, 6%, and 9% among the CD45- plasma cell population. Clinical trials are warranted in these diseases to learn the therapeutic benefit of anti-CD52 immunotherapy.
VITAMINDAND ITSANALOGS ASREGULATORS OFIMMUNEACTIVATION ANDANTIGENPRESENTATION
Griffin, Matthew D. , Xing, Nianzeng , Kumar, Rajiv , Griffin, Matthew D

Mayo Clinic

Annual Review of Nutrition | March 25, 2003 | Volume: 23 | Issue: 1 | Pages: 117-145

10.1146/annurev.nutr.23.011702.073114 | PMID 12651965 Get It

▪ Abstract It has been a little more than 20 years since the first appreciation that the biologically active hormonal form of the secosteroid vitamin D—classically categorized as a regulator of calcium/phosphorous metabolism and bone mineralization—can exert effects on cells of the immune system. Since then a substantial literature has accumulated to suggest that these effects are exerted on multiple immune cell types, are predominantly suppressive at pharmacologic levels, and are potent enough to have true therapeutic potential in the management or prevention of immune-mediated diseases. Less clear at present, however, are the physiological roles played by the vitamin D endocrine system in the regulation of normal and abnormal immune responses. In this review, an appraisal of the current understanding of vitamin D–mediated immune regulation is presented that emphasizes progress towards its clinical application as well as the manner in which emerging models of normal immune function may facilitate a more complete understanding of its physiologic significance.
Prognostic value of angiogenesis in solitary bone plasmacytoma
Kumar, Shaji , Fonseca, Rafaël , Dispenzieri, Angela , Lacy, Martha Q. , Lust, John A., Wellik, Linda, Kyle, Robert A. , Greipp, Philip R., Rajkumar, S. Vincent , Witzig, Thomas E. , Gertz, Morie A. , Rajkumar, S Vincent , Dispenzieri, Angela , Fonseca, Rafael

Mayo Clinic

Blood | February 12, 2003 | Volume: 101 | Issue: 5 | Pages: 1715-1717

10.1182/blood-2002-08-2441 | PMID 12393501 Get It

Angiogenesis plays an important role in the biology of multiple myeloma (MM) and has prognostic importance in this disease. Solitary plasmacytoma is a localized plasma cell malignancy that progresses to MM in a significant number of patients. We examined if angiogenesis is increased in solitary plasmacytoma and if it can help identify patients likely to progress to myeloma. We studied angiogenesis in plasmacytoma biopsy samples and bone marrow biopsies from 25 patients. High-grade angiogenesis was present in 64% of plasmacytomas. In contrast, bone marrow angiogenesis was low in all patients. Patients with high-grade angiogenesis in the plasmacytoma sample were more likely to progress to myeloma and had a shorter progression-free survival compared with patients with low-grade angiogenesis (P = .02). Angiogenesis is increased in solitary plasmacytoma and is a significant predictor of progression to myeloma and provides further evidence of its importance in the pathogenesis of myeloma.
Modulation of Growth Factor/Cytokine Synthesis and Signaling by 1α,25-Dihydroxyvitamin D3: Implications in Cell Growth and Differentiation
Gürlek, Alper , Pittelkow, Mark R. , Kumar, Rajiv

Mayo Clinic

Endocrine Reviews | December 4, 2002 | Volume: 23 | Issue: 6 | Pages: 763-786

10.1210/er.2001-0044 | PMID 12466189 Get It

AbstractDistinct from its classic functions in the regulation of calcium and phosphorus metabolism as a systemic hormone, 1α,25-dihydroxyvitamin D3 [1α,25(OH)2D3] is involved in the local control and regulation of cellular growth and differentiation in various tissues, including epidermis (keratinocytes) and bone (osteoblasts and osteoclasts). In this review, the impact of 1α,25(OH)2D3 on growth factor/cytokine synthesis and signaling is discussed, particularly as it pertains to bone cells and keratinocytes. 1α,25(OH)2D3 not only regulates growth factor/cytokine synthesis but may also alter growth factor signaling. Recently discovered examples for such interactions are the interactions between the vitamin D receptor and the mothers against decapentaplegic-related proteins that function downstream of TGFβ receptors. Inhibitory effects of 1α,25(OH)2D3 on keratinocytes through TGFβ activation and IL-1α, IL-6, and IL-8 suppression may provide a rationale for its beneficial effects in the treatment of hyperproliferative skin disorders, whereas stimulatory effects through the epidermal growth factor-related family members and platelet-derived growth factor may be operative in its beneficial effects in skin atrophy and wound healing. Modulation of cytokines and growth factors by 1α,25(OH)2D3 during bone remodeling plays an important role in the coupling of osteoblastic bone formation with osteoclastic resorption to maintain bone mass.